RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REGENXBIO Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$7.15+0.23 (+3.25%)
Close on Oct 19, 2026
- Market cap
- $379.06M
- P/E (TTM)
- –
- Dividend yield
- –
REGENXBIO Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and royalty [Member] | $156.27M | $81.96M | $90.24M | $112.72M | $470.35M | $154.57M | $35.23M | $218.51M | $10.39M | – | 91.7% | +90.7% |
| Zolgensma and Itvisma Royalties [Member] | $83.18M | $81.51M | – | – | – | – | – | – | – | – | 48.8% | +2.1% |
| Zolgensma Royalties [Member] | $82.54M | $81.51M | $85.32M | $101.92M | $94.98M | $61.63M | $20.83M | – | – | – | 48.4% | +1.3% |
| Nippon Shinyaku Licenses [Member] | $72.90M | – | – | – | – | – | – | – | – | – | 42.8% | – |
| Service [Member] | $14.17M | $1.37M | – | – | – | – | – | – | – | – | 8.3% | +936.1% |
| Total Service Revenue [Member] | $14.17M | $1.37M | – | – | – | – | – | – | – | – | 8.3% | +936.1% |
| Nippon Shinyaku Services [Member] | $11.82M | – | – | – | – | – | – | – | – | – | 6.9% | – |
| Other [Member] | $2.35M | $1.37M | – | – | – | – | – | – | – | – | 1.4% | +71.9% |
| Itvisma Royalties [Member] | $641.00K | – | – | – | – | – | – | – | – | – | 0.4% | – |
| License [Member] | – | – | – | – | – | $3.50M | $3.50M | $176.07M | $1.05M | $4.30M | – | – |
| Other [Member] | – | – | – | – | – | – | – | – | $8.00K | $286.00K | – | – |
| Achievement Of Sales Based Milestone For Zolgensma [Member] | – | – | – | – | – | $80.00M | – | – | – | – | – | – |
| Abb Vie Collaboration And License Agreement | – | – | – | – | $370.00M | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Regenxbio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.